Present state of immunosuppressive therapy in liver transplant recipients


  • Potential conflict of interest: Nothing to report.


Key Points

1. Our increasing understanding of the signaling pathways and cellular interactions in transplant immunobiology has facilitated targeted strategies using novel immunosuppressive agents.

2. The pattern of immunosuppressive drug use in the United States continues to change, and the changes include the use of antibody induction therapy and the agents used in maintenance therapy.

3. The driving forces behind the development of new immunosuppressive regimens are the long-term complications of current immunosuppressive regimens (particularly renal dysfunction and metabolic disturbances). Liver Transpl, 2011. © 2011 AASLD.